A Randomized, Open-Label, Phase 2 Trial Examining the Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men With Non-metastatic Prostate Cancer and a Rising Serum Prostate Specific Antigen After Primary Therapy.
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2018
At a glance
- Drugs Leuprorelin (Primary) ; Sipuleucel-T (Primary)
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- Acronyms STAND
- Sponsors Dendreon Corporation
- 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
- 10 Jun 2017 Biomarkers information updated
- 06 Jun 2017 Results from NCT01431391, NCT01981122 and NCT01487863 studies presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History